Prenetics soars on IM8-fueled earnings call

Prenetics Group Limited ((PRE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Prenetics Group Limited’s latest earnings call painted a picture of a company in rapid transformation, powered by the explosive growth of its IM8 brand. Management struck an upbeat tone as they highlighted surging revenue, expanding margins, and a fortified balance sheet, while openly acknowledging near‑term losses and concentration risks as the business scales.

Record Full-Year Revenue and Exceptional Growth

Prenetics reported full‑year 2025 revenue of $92.4 million, a staggering 480% increase from the prior year, underscoring the scale of its turnaround. Management credited this performance largely to IM8, which has become the central growth engine of the group.

Fourth Quarter Surge

Momentum accelerated into year‑end, with Q4 2025 revenue jumping to $36.6 million, up 457% year over year and 55% sequentially. IM8 alone contributed $27.4 million in the quarter, confirming strong demand and growing brand resonance.

IM8 Rapid Scale and Run Rate

IM8 scaled from launch to a $120 million annualized revenue run rate in under 12 months, delivering $60.1 million for full‑year 2025. Around 40% of that revenue came from the U.S., and the brand is now present in roughly 30 international markets, highlighting its global potential.

Strong Gross Profit and Margins

Profitability at the gross level improved sharply, with Q4 gross profit soaring about 804% year over year to $21.7 million and a consolidated gross margin of 59%. For 2025, gross profit reached $48.9 million, up roughly 428%, while IM8 posted an even stronger gross margin of about 63%.

Improving Adjusted EBITDA Trends

Despite still posting losses, Prenetics demonstrated clear progress on operating leverage in 2025. The Q4 adjusted EBITDA loss narrowed to $2.3 million, a 70.4% improvement versus the prior year, bringing the full‑year adjusted EBITDA loss down 27% to $13 million.

Robust Balance Sheet and Divestitures

The company entered 2026 with approximately $171.1 million in adjusted liquid assets and no debt, providing a sizable cushion to fund growth. Recent divestitures, including ACT Genomics, Europa, and a 35% stake in Insighta, unlocked cash and sharpened focus on the higher‑margin consumer‑health opportunity.

Strong Unit Economics and Subscription Metrics

Management emphasized improving unit economics, citing a blended lifetime‑value‑to‑CAC ratio of about 3x and a payback period of roughly 3.4 months in 2025. New‑customer average order value climbed from $110 in 2025 to about $233 in early 2026, helped by new quarterly subscriptions, and around 80% of new customers now choose subscription plans.

Clear 2026 Guidance and Path to Profitability

Investors received a detailed roadmap as Prenetics reaffirmed IM8 2026 revenue guidance of roughly $180–$200 million, implying nearly 300% year‑on‑year growth. The company is targeting a consolidated gross margin near 60% and continues to guide toward achieving adjusted EBITDA profitability by the fourth quarter of 2027.

Operational and Marketing Efficiency via AI

A key driver of growth has been an aggressive, data‑driven marketing strategy centered on artificial intelligence. Prenetics is testing some 800–1,000 new ads each week with algorithmic optimization, and one AI‑created Instagram video achieved 233 million views, helping build an efficient top‑of‑funnel for customer acquisition.

Third-Party Validation

The company’s progress has begun to attract attention from the sell side, with research coverage initiated by ROTH Capital and Sidoti & Company. Both firms issued buy ratings and set 12‑month price targets of $36 and $30, respectively, signaling increasing institutional confidence in the story.

Continued Adjusted EBITDA Loss and Near-Term Widening

Management cautioned that adjusted EBITDA losses will widen in the near term as it doubles down on growth. For 2026, the company expects an adjusted EBITDA loss of about $16–$20 million, effectively trading short‑term profitability for market share and scale.

High Revenue Concentration in IM8

IM8 accounted for $60.1 million of the group’s $92.4 million in 2025 revenue, or roughly 65%, underlining its importance to the overall narrative. This concentration creates risk if IM8’s growth slows, faces competitive pressure, or encounters brand‑related challenges.

Historical Customer Acquisition Inefficiency

Management also acknowledged that 2025 began with inefficient customer acquisition economics, as blended AOV of $110 lagged CAC of about $130 and implied a ROAS of only 0.8x. While pricing and subscription changes have since improved returns, CAC has risen alongside AOV, making continued optimization essential.

Reliance on Heavy Marketing Investment

The growth plan remains heavily dependent on sustained and expanding marketing spend, initially anchored in Meta and Google. Prenetics is now actively diversifying into channels such as YouTube, TikTok, and podcasts, a strategy that broadens reach but also introduces execution risk and CAC volatility.

Legacy Crypto Exposure

The company continues to hold 510 BTC on its balance sheet, which adds an element of asset‑value volatility outside its core operations. While management has stopped additional crypto purchases, this position can still swing reported liquid assets with market moves.

Divestiture of Low-Margin Businesses

Recent sales of businesses like Europa underline how legacy operations included lower‑margin or noncore activities that diluted profitability. The pivot to a pure‑play consumer‑health model promises better margins but also brings execution risk as Prenetics scales and expands internationally.

Forward-Looking Guidance and Outlook

Looking ahead, Prenetics’ guidance leans bullish on top‑line expansion while staying realistic about continued investment. With IM8 expected to nearly triple revenue in 2026, margins targeted around 60%, and a roadmap to adjusted EBITDA break‑even by late 2027, management is betting that today’s heavy spend will translate into a durable, profitable consumer‑health platform.

Prenetics’ earnings call framed a company in high‑growth mode, with IM8 driving exceptional revenue and margin expansion on top of a strong balance sheet. Investors must weigh the impressive growth and improving unit economics against continued losses, marketing intensity, and product concentration, but the tone and numbers suggest a business moving decisively toward scale and eventual profitability.